Cibinqo (abrocitinib)
- Region
- 🇪🇺 EU
- Active substance
- abrocitinib
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Dermatitis, Atopic
- CHMP opinion
- Thu 14 Oct 2021
- EU approval
- Thu 09 Dec 2021
- Application
- EMEA/H/C/005452
- ATC
- D11AH08
- Official record
- www.ema.europa.eu
Indication
Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Cibinqo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.